Medifast stock: Zacks upgrades Medifast stock to Strong Buy

Published on 10/23/2026 at 07:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zacks Research upgraded Medifast from Hold to Strong Buy on October 15, 2026. Medifast stock faces an October 26, 2026 results date.

Analyst shift and earnings date

Zacks Research upgraded Medifast from Hold to Strong Buy on October 15, 2026.
Second-quarter revenue reached USD 76.38 million, down 27.60 percent year over year.
Medifast is scheduled to report third-quarter results on October 26, 2026.

MED, US58470H1014, Illustration mit AI erstellt.

Medifast (ISIN US58470H1014) received a Strong Buy upgrade from Hold by Zacks Research on October 15, 2026, according to MarketBeat. The change arrives before the company's scheduled third-quarter results and adds a more constructive view to a mixed analyst picture.

Rating change meets a weak quarter

The upgrade follows Medifast's second-quarter report for the period ended June 30, 2026. Revenue was USD 76.38 million, down 27.60 percent from the year-earlier period, while net loss was USD 3.10 million, according to Yahoo Finance.

The operating mix offered a counterpoint to the revenue decline. Active earning coaches fell 48.70 percent year over year to approximately 11,700 in the second quarter, but revenue per active earning coach rose 41.00 percent to USD 6,529, marking a third consecutive quarter of productivity growth, Yahoo Finance reported on October 6, 2026.

What does the October 26 date mean?

Medifast plans to announce results for the quarter ended September 30, 2026, before the market opens on October 26, 2026. The conference call is scheduled for 8:30 a.m. ET that day, according to Morningstar. MarketBeat cited a consensus estimate of USD 71.30 million in revenue and a loss of USD 0.35 per share for the third quarter.

Three events set the timeline

On August 3, 2026, Medifast reported second-quarter revenue of USD 76.38 million and a loss of USD 0.28 per share, beating the cited loss estimate of USD 0.65 per share, MarketBeat reported. On October 6, 2026, Yahoo Finance highlighted the 41.00 percent productivity increase. On October 15, 2026, Zacks Research upgraded the rating to Strong Buy, as reported by MarketBeat.

Dates for the next report

The next scheduled company event is the third-quarter 2026 results announcement on October 26, 2026. The related conference call begins at 8:30 a.m. ET on October 26, 2026, according to Morningstar.

Market position and company profile

Medifast is listed on the NYSE under ticker MED and describes its business as a science-backed, coach-guided metabolic health system. Its cash balance was USD 71.91 million at June 30, 2026, while operating cash flow was USD 1.70 million for the second quarter.

Market capitalization stood at USD 136.1 million as of October 22, 2026. The 52-week range was USD 9.22 to USD 13.45 as of that date. The further course of trading is shown by the continuously updated real-time quote of Medifast stock.